CEL-SCI Raises $2.5M in Stock Offering to Fund Multikine Development
Event summary
- CEL-SCI priced a best-efforts offering of 2.5M shares at $1.00 per share, raising $2.5M before fees.
- Proceeds will fund Multikine development, general corporate purposes, and working capital.
- Offering expected to close June 16, 2026, under a shelf registration statement filed July 2025.
- ThinkEquity acted as sole placement agent for the transaction.
The big picture
This $2.5M equity raise reflects ongoing challenges in biotech financing, where clinical-stage companies must balance development costs with market volatility. CEL-SCI's focus on Multikine highlights the strategic importance of immune-boosting therapies in oncology, though competition remains fierce. The offering's structure suggests cautious optimism about securing necessary capital while minimizing dilution.
What we're watching
- Clinical Progress
- How Multikine's development timeline will be impacted by this funding.
- Market Positioning
- Whether CEL-SCI can maintain momentum in competitive cancer immunotherapy space.
- Execution Risk
- The pace at which CEL-SCI can translate capital into tangible development milestones.
Related topics